ArticleTherapeutics and clinical risk management2018

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation.

Zhan-Miao Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.